Pandemic Timeline

Kim Hansik files patent KR20210028065: Physiological saline containing graphene dispersion and corona virus vaccine using the same

The present invention relates to an injection solution, a physiological saline solution, a glucose solution, and an IV, which are to be administered in a blood vessel and subcutaneous tissue of the human body for the purpose of curing a disease. A physiological saline solution containing graphene dispersed therein according to the present invention and a corona virus vaccine using the same are intended to be used for each disease including dementia, Parkinson′s disease, Lou Gehrig′s disease, Huntington′s disease, and the like. The physiological saline solution containing graphene dispersed therein according to the present invention and the corona virus vaccine using the same are intended to be used as a therapeutic agent for viruses such as MERS, SARS, Corona virus, and the like, and are also used as a therapeutic agent by dispersing graphene powder with a size of 0.2 nm or less in a means used as an injection solution such as an injection solution, an IV, a physiological saline solution, and a glucose solution used in conventional hospitals. The IV with the graphene powder dispersed therein is injected into the human body where the virus has penetrated, and when the virus and graphene powder meet, the graphene powder and the virus are attracted to each other by nano-cohesion. When graphene powder adheres to the body and spike projections of the virus, the virus cannot function properly and cannot proliferate and eventually die. In the present invention, a process of mixing and dispersing the corona virus cultured in physiological saline containing graphene dispersed therein is repeated, and thus the graphene nanopowder invades each microscopic organ of the spike protrusion of the corona virus to decrease the function of the corona virus, stop functioning thereof, or kill some coronaviruses, resulting in a coronavirus vaccine.

Patent KR1020200054820A

Sources:

 

 

Comments are closed.